A meta-analysis involving more than 70,000 participants with type 2 diabetes (SMART-C) found that the cardiovascular benefits of SGLT-2 inhibitors, including reductions in MACE, cardiovascular death, hospitalisation for HF, and CKD progression, were consistent regardless of whether patients were receiving a GLP-1 receptor agonist at baseline [19]
But the doses involved are 1000-3000 mg daily, far exceeding the 2 mg in compounded semaglutide injections
The Bottom Line About Semaglutide Dosages Semaglutide is a powerful medication with proven benefits for type 2 diabetes and weight management
The breadth of bacteriophages contributing to the development of the phage-based vaccines for COVID-19: an ideal platform to design the multiplex vaccine
The study in Nature Medicine did not report on eye diseases, however, says Aleksandra Rachitskaya, MD, a vitreoretinal surgeon at the Cole Eye Institute